Keywords: lilly, synaptic, begin, phase, iii, migraine, drug

Lilly and Synaptic Begin Phase III for Migraine Drug

Article | 08 September 1998

Print This

Eli Lilly and research partner Synaptic Pharmaceutical have agreed tobegin Phase III testing of a selective 5-HT1F receptor agonist ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in